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ABSTRACT 
 
Chronic renal failure patients develop a coagulopathy primarily due to reversible 
platelet dysfunction. This coagulopathy makes certain anaesthetic techniques and 
procedures such as neuraxial anaesthesia and invasive line placement possibly 
contra-indicated or risky. There is no evidence to suggest that the degree of platelet 
dysfunction is proportional to the degree of renal dysfunction. In this research project 
the platelet function of 39 end stage renal failure patients, who received regular 
dialysis and who presented to theatre for vascular access, was assessed using the 
thromboelastogram. A bleeding time was also performed pre-operatively. A linear 
regression model was used to determine if the bleeding time, plasma urea, plasma 
creatinine or creatinine clearance could predict maximum amplitude (and therefore 
clot strength) on the thromboelastogram. No such regression could be found. The 
clinical implication of this result is that there exists no "safe" plasma urea or 
creatinine, below which it is safe to perform procedures which are contra-indicated in 
coagulopathies. The degree of renal dysfunction did not predict the degree of 
platelet dysfunction. Since dialysis reverses the platelet dysfunction, the question 
that should be asked before performing such a procedure is not "how severe is the 
renal dysfunction?" but rather "has the patient been receiving regular dialysis?" 
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    CHAPTER ONE 
OVERVIEW OF THE STUDY 
 
1.1  Introduction 
Chronic renal failure patients are at greater risk for bleeding. The cause of the bleeding 
is multi factorial and includes platelet dysfunction1, alterations in the fibrinolytic system, 
and vascular abnormalities2. 
This problem is further compounded by the fact that many of these patients receive 
haemodialysis, which by itself can activate platelets, coagulation and fibrinolysis3-4.  The 
process of haemodialysis affects haemostasis due to the nature of the composition of 
the circuit, contact with the dialysis membrane, altered rheology of blood in the circuit as 
well as any additional anticoagulants5. 
The major contributing factor to the bleeding diathesis in chronic renal failure patients 
remains platelet dysfunction6-8. There are many methods to measure platelet function. 
Similarly they all measure the same end point, i.e. clot formation. Older techniques such 
as bleeding times and absolute platelet counts are no longer utilized alone due to poor 
specificity and sensitivity9. Newer technologies for measuring platelet aggregation have 
become available. One of these is the thromboelastogram (TEG®). The 
thromboelastogram provides information about the entire coagulation system in a 
graphic format, which not only gives information about clot formation but also about clot 
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lysis. Information about the different components of coagulation can be extrapolated 
from the graphic data including platelets, fibrin, thrombin and other clotting factors. The 
maximal amplitude (MA) of the graph is an indication of platelet and fibrin function, i.e. 
clot integrity10. 
In anaesthesia certain procedures are contra-indicated if the patient has a 
coagulopathy. This includes the platelet dysfunction associated with chronic renal 
failure. These procedures include neuraxial anaesthesia such as spinals and epidurals, 
certain nerve plexus blocks and placement of invasive lines such as central venous 
catheters. Chronic renal failure patients are also at higher risk for post-operative 
bleeding complications11. 
 
1.2  Background to the study 
Patients with renal dysfunction pose an interesting dilemma to the anaesthetist. It is well 
known that their platelets are dysfunctional, but what is not known is at which point 
during the renal failure the platelet dysfunction becomes clinically significant. 
Traditionally anaesthetists have used arbitrary “cut-off” values for plasma urea, above 
which it is deemed unsafe to perform invasive anaesthetic techniques such as neuraxial 
anaesthesia. This arbitrary value varies greatly between anaesthetists and has no 
scientific evidence to support it. 
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1.3  Problem Statement 
Anaesthetic interventions may be contra-indicated in chronic renal failure patients due 
to the presence of a coagulopathy. There is no evidence to suggest that this dysfunction 
can be quantified by using the TEG®, or that this dysfunction is proportional to the renal 
failure. 
 
1.4  Purpose of the study 
1.4.1 Aim 
The aim of this study was to investigate whether patients with end stage renal failure, 
presenting for surgery, had a coagulopathy in the form of platelet dysfunction. 
 
1.4.2 Objectives 
1.4.2.1 Primary Objective 
The primary objective of this study was to confirm and quantify the presence of platelet 
dysfunction in patients with chronic renal failure presenting for surgery. 
1.4.2.2 Secondary Objective 
The secondary objective of this study was to describe a correlation, if any, between the 
severity of the renal dysfunction and the platelet dysfunction. 
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1.5  Research Assumptions 
The following definitions were used within the scope of this study: 
 Chronic Renal Failure12: “Kidney damage for more than three months, as defined 
by structural or functional abnormalities of the kidney, with or without decreased 
glomerular filtration rate (GFR) manifest by either pathological abnormalities or 
markers of kidney damage, including abnormalities in the composition of the blood 
or urine, or abnormalities in imaging testing OR GFR less than 60 ml/min/1.73m² for 
more than three months, with or without kidney damage.” 
 End stage renal disease12: “GFR of less than 15 ml/min/1.73m² or patients 
requiring chronic dialysis (also termed stage five chronic renal disease).” 
 Uraemic bleeding: Any bleeding due to the coagulopathy of chronic renal disease. 
 Coagulopathy: a disease affecting the coagulability of blood; that is the ability of 
blood to clot. 
 Thromboelastography: A laboratory investigation where a small whole blood 
sample is allowed to clot in a cup. A pin, suspended and rotated in the cup, interacts 
with the clot formed. The interaction with the clot is transduced to an electrical signal 
which is analysed. The data is presented in a graphic format, the 
thromboelastogram. 
 Glomerular Filtration Rate (GFR)13: Amount of fluid filtered at the glomerulus in 
the kidney measured in ml/min. GFR is an indication of kidney function. It is 
calculated using the Cockcroft-Gault formula which is as follows: 
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                     (Constant = 1.23 in males and 1.04 in females) 
 
1.6  Demarcation of the study 
1.6.1 Chris Hani Baragwanath Hospital 
The study was conducted in the JD Allen theatre complex of the Chris Hani 
Baragwanath hospital. 
1.6.2 Charlotte Maxeke Johannesburg Academic Hospital 
The study was conducted in the main theatre complex of the Charlotte Maxeke 
Johannesburg Academic Hospital. 
. 
 
1.7  Ethics 
1.7.1 Approval was obtained from the University of the Witwatersrand Human Research 
Ethics Committee on 29 August 2008, Ref R14/49 Wels (Appendix B) 
1.7.2 Permission was granted from management of the Chris Hani Baraqwanath 
Hospital and Charlotte Maxeke Johannesburg Academic Hospital respectively. 
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1.7.3 Informed consent was obtained from all patients after explaining the study to 
them. This consent was recorded on a consent form (Appendix C). 
1.7.4 Approval of the study was granted by the Post Graduate Committee  
(Appendix D). 
The research was conducted in keeping with the principles of the Declaration of Helsinki 
(2009)14. 
 
1.8 Summary of Methodology 
This study is a contextual, prospective, descriptive study. As no other research has 
been conducted on this topic it is a small pilot study. 
A Sample size of at least thirty was needed. The sampling was done according to a 
consecutive sampling method15. 
To be included in the study the patients had to be adults, 18 years and older, in a 
capacity to give informed consent. They were all end stage renal failure patients 
classified as grade five chronic kidney disease and enrolled on the chronic 
haemodialysis program at CMJAH or Chris Hani Baragwanath Hospital. Patients were 
booked for theatre for vascular access and were dialysed in the 48 hour period prior to 
surgery. Patients had a full blood count, plasma urea and creatinine performed prior to 
surgery. 
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Any patient with a diagnosed and confirmed bleeding disorder not related to renal failure 
or on any anticoagulation therapy was excluded from the study. 
 
Patients were recruited from the Charlotte Maxeke Johannesburg Academic Hospital 
and Chris Hani Baragwanath Hospital. 
 
Once anaesthetised and before the commencement of surgery the principal investigator 
sampled venous blood from the patient and performed a TEG® on the blood sample. 
The principal investigator also performed a bleeding time. The patient’s name, blood 
investigation results, TEG®, and the bleeding time were recorded on a data sheet. 
 
Data was summarized using descriptive statistics. This includes mean, standard 
deviation and 95% confidence interval. Regression modeling was explored along 
ordinary least squares multiple linear regression. 
 
1.8 Clinical importance of the Study 
The study aimed to confirm the presence of platelet dysfunction in chronic renal failure 
patients. If this platelet dysfunction could be predicted, guidelines and precautions can 
be put into place to limit risk from bleeding or blood loss in renal failure patients coming 
to theatre. 
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1.9 Validity and Reliability 
It was not necessary to standardize the general anaesthetics used in this study as none 
of the anaesthetic techniques affected coagulation. The principal investigator received 
training on calibration and test running of the TEG® by a certified Laboratory Technician 
from the manufacturer. The TEG® at both hospitals were calibrated daily by the 
principal investigator with control tests provided by the manufacturer. All TEG® tests 
were performed by the principal investigator as per manufacturer instructions. All 
reagents were new and not expired and stored as per manufacturer requirements. The 
principal investigator personally performed all bleeding times as per standard protocol. 
 
1.10 Limitations of the Study 
Patient numbers were a limiting factor as only two or three patients received surgery per 
vascular access list, and the lists were not regular. This study is contextual and there 
was no randomization of patients. This is a pilot study but was deemed necessary to 
determine if further investigation is warranted. 
 
1.11 Research Report Outline 
This research report will comprise the following chapters: 
Chapter One: In this chapter an introduction and overview of the research project is 
discussed, including the problem statement and a summary of the research 
methodology. 
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Chapter Two: This chapter looks at currently available literature which deals with this 
research topic.  
Chapter Three: In this chapter the research methodology is discussed in more detail. 
Chapter Four: The data is presented and described. 
Chapter Five: In the final chapter the analysed data is discussed. Conclusions are 
drawn and recommendations made. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Introduction 
Chronic renal failure patients are at greater risk for bleeding. The cause of the bleeding 
is multi-factorial and includes platelet dysfunction1, alterations in the fibrinolytic system 
and vascular abnormalities2. 
 
2.2    Normal Coagulation 
2.2.1 Initiation of Coagulation 
The major stimulus to trigger coagulation is blood vessel wall damage. Any damage, 
whether mechanical, chemical or electrical results in the activation of the endothelium 
and the expression of P-selectin on the cell surface16. This vessel damage also 
activates platelets, which also express P-selectin on their surfaces. These P-selectin 
molecules bind to to P-selectin glycoprotein ligands-1 (PSGL-1), which occur on 
monocytes and neutrophils17. Once bound this promotes the “rolling” of platelets and 
leukocytes against the wall of the damaged vessel18. 
Von Willebrand factor (vWF) is a protein contained in the Weibel-Palade bodies of 
endothelial cells, as well as in the alpha granules of platelets. When released after 
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vessel damage it binds to glycoprotein Ib (GPIb) on the surface of platelets and 
exposed subendothelial connective tissue. It promotes the adhesion of platelets at the 
site of injury19. Von Willebrand factor also binds to the Glycoprotein IIbIIIa (GPIIbIIIa) 
receptor on platelets enhancing platelet aggregation. 
Tissue factor is a glycoprotein present in endothelial cells. When vessel damage occurs, 
this tissue factor is exposed. Tissue factor has a very strong affinity for factor VII. Once 
bound, tissue factor and factor VII form an activated tissue factor, factor VIIa complex, 
which has enhanced catalytic properties. The tissue factor-VIIa complex activates factor 
IX to IXa and X to Xa. Factor Xa activates factor V which has been released from the 
alpha granules20-21. Prothrombin, which is bound to the GPIIbIIIa receptor on the 
activated platelet, is converted to thrombin by Xa. Note that only small quantities of 
thrombin are formed in this fashion. The majority of thrombin is produced during the 
amplification phase22. 
 
Figure 2.1 Platelet Aggregation 
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2.2.2 Amplification phase 
The small amount of thrombin produced in the initiation phase activates more platelets, 
factor V and factor XI (Factor XI is bound to the GPIb receptor of activated platelets). 
XIa activates IX to IXa. Both the IXa produced here and the IXa generated from the 
tissue factor-VII complex diffuse to the surface of activated platelets and bind to the 
membrane23. Von Willebrand factor is also bound to GPIb/IXa. In normal plasma vWF is 
bound to VIII. When thrombin is produced it separates the two and activates VIII to 
VIIIa. The VIIIa binds to GPIb/IXa complex and in the presence of calcium activates 
additional factor X21. 
 
Figure 2.2 Clotting Cascade 
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2.2.3 Propagation 
The VIIIa/IXa complex is called the tenase complex. This tenase complex, together with 
calcium ions, produces large amounts of Xa. Xa together with Va and calcium form the 
prothrombinase complex that produces the thrombin needed to convert fibrinogen to 
fibrin. Thrombin also catalyzes its own production by activating factors V,VIII and XI21. 
 
2.3 Pathophysiology of coagulopathy in chronic renal failure 
The pathophysiology of uraemic bleeding is multifactorial. Chronic renal failure patients 
are often older and have many co morbidities such as hypertension and atherosclerotic 
vascular disease24. As such they are often on anti-platelet drugs and anticoagulants. 
Sohal et al11 grouped the mechanisms of uraemic bleeding into five main categories. 
i.) Defective interaction of platelets with vessel walls. 
ii.) Defective platelet secretion. 
iii.) Defective platelet aggregation. 
iv.) Anaemia. 
v.) Other factors. 
Zwangiga et al25 demonstrated adhesion defects in platelets at high shear rates in 
chronic renal failure patients. Since von Willebrand Factor (vWF) levels are normal or 
raised in chronic renal failure patients the there appears to be a qualitative rather than a 
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quantitative dysfunction between vWF and platelet glycoproteins26. Chronic renal failure 
patients also have higher prostacyclin levels, which inhibit platelet aggregation27, and 
higher nitric oxide (NO) levels28 which cause vasodilatation and also inhibit platelet 
function. 
Deficient stores of Adenosine Diphosphate (ADP) and serotonin, as well as defective 
production of thromboxane A2 (TXA2) have all been described in chronic renal failure 
patients29-31. 
Moal et al32 found that resting GPIIbIIIa expression was normal in chronic renal failure 
patients, hence the abnormal aggregation due to a qualitative rather than quantitative 
defect of this receptor. As haemodialysis improves fibrinogen binding to GPIIbIIIa, it 
appears as if a dialyzable toxin accounts for this inhibition. Kaplan et al33 made a 
detailed quantitative study of these uraemic toxins which he calls “middle molecules”. 
Fibrinogen Fragments (FF) are among these molecules and implicated by Kaplan as the 
substance responsible for inhibiting platelet aggregation. Thekkedath et al6 
demonstrated that these FF do in fact inhibit platelet aggregation by competing with 
fibrinogen at the GPIIbIIIa receptor, and that this inhibition is reversible by removing the 
FF by haemodialysis. 
Anaemia is common in chronic renal failure patients34. In normal rheological flow within 
blood vessels the bulk of the red cell mass travels in the centre of the lumen in a 
laminar fashion. This displaces plasma and platelets, which travel in close proximity to 
the endothelium, promoting interactions between the platelets and vessel walls. Red 
cells also produce ADP and TXA2 which enhance platelet function35-36. 
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Other factors which play a role in uraemic bleeding include drugs and haemodialysis. 
Due to co-morbidities chronic renal failure patients are often on anti-platelet drugs or 
anticoagulants. Chronic renal failure patients are at an increased risk of bleeding 
compared with normal patients taking these drugs37-38. 
Finally the process of haemodialysis activates platelets, coagulation and fibrinolysis, 
and often anticoagulants are added to the circuit3-5. This may also contribute to the 
coagulopathy.  
 
2.4  Tests for platelet function 
 
2.4.1 Traditional Methods 
The platelet count remains the first line test of platelet function. Platelets were 
traditionally counted manually but today automated cell counters are used. Automated 
cell counters use optical or flow cytometric methods to count platelets. Optical counters 
identify platelets by their light scattering properties or fluorescence after the addition of 
dye39-40. Flow cytometric methods identify platelets by fluorescent monoclonal 
antibodies to antigens on the platelet membranes41. 
The in vivo bleeding time was first described by Duke in 1912 and was the first in vivo 
test of platelet function. It is poorly reproducible, invasive, insensitive and time 
consuming42. However the bleeding time is still used as a first line screening test for 
severe haemostatic defects like von Willebrand’s disease43. The clear advantage of the 
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bleeding time is that it studies natural haemostasis and does not require expensive 
equipment. 
 
2.4.2 Platelet aggregometry 
Turbidmometric platelet aggregometry was developed in the 1960’s and became the 
gold standard to test platelet function. Platelet rich plasma is stirred in a cuvette 
between a light source and a photocell. An agonist such as ADP is added and the 
platelets aggregate. The resultant increased transmission in light is used as a function 
of platelet function44. Today aggregometry is measured by electrical impedance of 
whole blood or by light scattering methods45-46. 
 
2.4.3 In vitro platelet function simulation 
Platelet aggregometry does not mimic physiological processes in vivo. Newer tests 
attempt to simulate the process of platelet activation and aggregation that occur in vivo 
after vessel wall damage47. 
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2.4.3.1 Clot Signature Analyser 
This technique involves punching holes into a tube that contains non anti-coagulated 
blood and results in the formation of a primary haemostatic plug. Alternatively collagen 
is added to the tube which results in thrombus formation48. 
 
2.4.3.2 Platelet Function Analyser (PFA) 
Platelets in citrated whole blood are exposed to high shear conditions within capillary 
tubes. The flow rate is monitored as platelets form a plug within the centre of a 
membrane coated with collagen and ADP or adrenaline. The test parameter is called 
the closure time (CT)49. 
 
2.4.3.3 Cone Platelet Analyser 
This test is based upon the adhesion of platelets to an extra cellular matrix under flow 
conditions. It consists of a cone and plate device in which a blood sample is exposed to 
a plastic plate under arterial flow conditions. Platelet adhesion and aggregation on the 
surface of the plate are recorded by an image analyser50. 
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2.4.3.4 Measuring physical properties of the clot 
Physical properties of a clot include formation, retraction and lysis. Retraction and lysis 
can be measured by calculating the differences in volumes pre and post clotting. 
 
2.4.3.5 Thromboelastography  
Thromboelastography was developed in 1948 as a research tool, but rediscovered in 
the 1980’s. The TEG® device monitors the interaction of platelets within the fibrin mesh 
of the clot during formation and lysis. The device consists of a cylindrical cup that holds 
a whole blood sample at 37˚C and is oscillated in a rotation cycle of 10 seconds. As the 
clot forms the torque of the rotating cup is transmitted to an immersed pin. The pin 
rotation is converted to an electrical signal via a transducer. The strength of the 
developing clot increases the magnitude of the output, and conversely decreases during 
clot lysis51-52. 
The TEG® gives a graphic representation (fig 2.3) of the changes in viscoelasticity at all 
stages of the developing and resolving clot. The parameters include the reaction time (R 
Value, an indication of factor activation and initial fibrin formation), the alpha angle and k 
value (an indication of the speed of clot formation), the maximal amplitude (MA, an 
indication of platelet aggregation and clot integrity) and the clot lysis (CL, an indication 
of clot breakdown)53. 
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Figure 2.3: A typical Thromboelastogram 
     
Figure 2.4: The “cup and pin” of the TEG®  
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Figure 2.5: Interpretation of TEG® Graphs 
Thromboelastography can be performed on different blood samples. Native blood (non-
activated blood) can be placed directly into the cup. This however requires that sampled 
blood be placed directly into the cup with as little delay as possible. Activated blood 
(using Celite or Kaolin particles) clots faster as these particles activate factor XII, thus 
giving a thromboelastograph result in less time than native blood. To facilitate transport 
citrated blood can be used. The sample needs to be recalcified before performing the 
test. This is done by adding 20 µl of Calcium Chloride to 340 µl citrated blood in the 360 
µl cup. Heparinase is an enzyme which cleaves heparin into inactive fragments without 
affecting the other components of coagulation. TEG® cups impregnated with 
heparinase are available to determine if the coagulation status is as a result of 
administered heparin54. 
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2.4.3.5.1 Clinical application of Thromboelastography 
Thromboelastrography is currently used in Liver transplantation, Cardiopulmonary 
Bypass, for the assessment of blood product administration, specifically in Obstetric and 
Trauma surgery, and to assess coagulation before regional anaesthesia. It can also be 
applied to monitor the efficacy of anticoagulant and antiplatelet drugs54. 
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CHAPTER 3 
RESEARCH METHODOLOGY 
 
3.1 Introduction 
Chronic renal failure patients are at greater risk for bleeding. The cause of the bleeding 
is multi factorial and includes platelet dysfunction1, alterations in the fibrinolytic system, 
and vascular abnormalities2. 
In anaesthesia certain procedures are contra-indicated if the patient has a 
coagulopathy, including chronic renal failure platelet dysfunction. These include 
neuraxial anaesthesia such as spinals and epidurals, certain nerve plexus blocks and 
the placing of invasive lines such as central venous catheters. Chronic renal failure 
patients are also at higher risk for post operative bleeding complications11. 
 
3.2 Study Design 
This is a contextual, prospective, descriptive pilot study. Prospective, as informed 
consent was obtained prior to data collection, and descriptive as the clotting profile of 
chronic renal failure patients was examined and described. Since no other research has 
been conducted on this topic it is a small pilot study. 
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3.3 Study population 
Patients were selected from elective vascular access lists at Chris Hani Baragwanath 
Hospital and Charlotte Maxeke Johannesburg Academic Hospital. All patients were on 
the chronic dialysis program at the respective hospitals. 
 
3.4 Study Sample 
This pilot study set out to determine the relationship between the maximum amplitude 
from the TEG® and parameters from laboratory investigations i.e. platelet count, 
creatinine clearance and a bedside bleeding time. 
For a regression study at least 10 subjects are included for each regressor or variable of 
interest. Since it was very likely that not all predictor variables under study would 
contribute significantly to the regression line of interest a sample size of at least 30 was 
required.  
The sampling was done according to a consecutive sampling method15. 
 
3.5 Study Period 
The study was conducted during the period from October 2008 to March 2010. 
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3.6 Inclusion criteria 
 Adult patients, 18 years and older, in a capacity to give informed consent. 
 End stage renal failure patients classified as grade five chronic kidney disease by 
international convention. 
 Patients had to be receiving chronic haemodialysis at the Charlotte Maxeke 
Johannesburg Academic Hospital or Chris Hani Baragwanath Hospital. 
 Patients had to be coming to theatre for vascular access (creation of an arterio-
venous fistula or insertion of a permanent indwelling catheter). 
 Patients had to have been dialysed in the 48 hour period prior to surgery. 
 Patients had to have a full blood count, plasma urea and creatinine performed 
prior to surgery. 
 
 3.7 Exclusion criteria 
 Any patient with a diagnosed and confirmed bleeding disorder not related to renal 
failure. 
 Any patient on anticoagulation therapy other than heparin used during dialysis 
 Any patient less than 18 years of age, or greater than 18 years of age but unable 
to give informed consent. 
 
3.8 Data collection  
Patients were recruited from the Charlotte Maxeke Johannesburg Academic Hospital 
and Chris Hani Baragwanath Hospital.  
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Patients booked for elective vascular access surgery (Permanent Catheter insertion or 
Arterio-venous fistulae creation) were approached by the principal investigator and 
interviewed. They were informed about the study and invited to participate provided they 
met all inclusion criteria. 
After agreeing to participate, and a full explanation of the requirements, an informed 
consent form was signed by the patient and the principal investigator. They were 
allowed to withdraw from the study at any time. 
 
Pre-operative blood investigations as per inclusion criteria were taken on the day before 
surgery by the Dialysis Unit staff when the patients presented for dialysis. 
 
Once in theatre and anaesthetized, before the commencement of surgery, the principal 
investigator sampled venous blood from the patient and performed a TEG® of the blood 
sample. The principal investigator also performed a bleeding time. The principal 
investigator chose to perform a bleeding time together with the TEG® to obtain a full 
evaluation of the patients platelet function and to correlate the findings of the two tests. 
 
The patient’s name, blood investigation results, the TEG®, and the bleeding time were 
recorded on a data sheet. 
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3.9 Data Analysis 
Data were summarized using descriptive statistics e.g. mean standard deviation and 
95% confidence interval. Correlation matrices and regression modeling were explored 
along ordinary least squares multiple linear regression with the assistance of a 
biostatistician.  Data were analysed using Statistica version 9.1. 
 
3.10 Validity and Reliability 
It was not necessary to standardize the general anaesthetics used in this study as none 
of the anaesthetic techniques affected coagulation. The principal investigator received 
training on calibration and TEG® test running by a certified Laboratory Technician from 
the manufacturer. The TEG® at both hospitals was calibrated daily by the principal 
investigator with control tests provided by the manufacturer. All TEG® tests were 
performed as per manufacturer instructions. All reagents were new and not expired and 
stored as per manufacturer requirements. The principal investigator performed all 
bleeding times as per standard protocol. 
 
3.11 Funding 
Both hospital sites had fully functional TEG® machines. The consumables and 
disposables (cups, pins, reagents and disposable pipette tips) were all generously paid 
for by the Wits Donald Gordon Medical Centre. 
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     CHAPTER 4 
RESULTS AND STATISTICAL ANALYSIS 
 
4.1 Introduction 
In this chapter the results of the patient’s laboratory investigations i.e. Full blood count 
(haemoglobin and platelets), urea and creatinine (as well as calculated GFR Rate using 
the Cockgraft-Gault formula) and the results of the bedside tests i.e. the bleeding time 
and the Thromboelastogram are described using descriptive statistics. The results are 
analyzed to determine if the GFR can predict platelet function (MA on 
Thromboelastogram). 
 
4.2 Descriptive Statistics of Laboratory and Bedside test results 
Descriptive statistics are used to describe the data collected in table 4.1. Thirty-nine 
patients were enrolled in the study. Fifteen of the 39 patients were male. Only two 
patients had abnormal platelet counts. The GFR was calculated using the Cockgraft-
Gault formula. This formula incorporates serum creatinine, age, weight and sex (see 
research assumptions chapter one for formula). 
Thirteen patients had MA values greater than 69mm, which implies a hypercoagulable 
state. Only two of the 39 patients had MA values less than 51mm. These two patients 
also had prolonged Reaction times (R value) which indicate a hypocoagulable state. 
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Table 4.1 Descriptive statistics of the Data  
Variable Description 
Number of patients (N) 39 
Age (years) 
Mean ± SD 
44 ± 10 
Sex (%) 38% Male / 62% Female 
Haemoglobin (Hb) (g/dl)  
Median and Range 
10.2  
(14.3 – 18.3) 
Platelet count 
Median and Range 
212 
(137 – 373) 
Urea (mmol/l) 
Median and Range 
14.2 
(2.6 – 7.0) 
Creatinine (µmol/l) 
Median and Range 
504 
(60 – 120) 
Glomerular Filtration Rate (ml/min) 
Median and Range 
14.3 
(90 – 140) 
Bleeding Time (BT) (min) 
Median and Range 
10 
(0 – 9) 
R Value (min) 
Median and Range 
7.4 
(2 – 8) 
K Value (min) 
Median and Range 
1.3 
(1 – 3) 
Alpha Angle (degrees) 
Median and Range 
72 
(55 – 78) 
Maximum Amplitude (MA) (mm) 
Median and Range 
64 
(51 – 69) 
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4.3 Statistical Analysis 
A correlation study of the variables was performed and presented in table 4.2. It is clear 
from the p values (those less than 0.05 being statistically significant) that only two 
variables correlate with the MA, namely the haemoglobin and the platelet count. The 
GFR showed no correlation to the MA. Patient 38 was excluded because of missing 
data as the patient’s bleeding time was undetermined (the patient failed to clot in the 
time allotted).  
Table 4.2 Correlation Matrix of the Data 
 Hb Platelet Urea Creat BT R  K α MA GFR Age 
Hb 1.0000 -.3687 -.1579 -.0957 -.0692 .3514 .4549 -.1301 -.4433 .1084 -.2854 
 p= --- p=.023 p=.344 p=.568 p=.680 p=.030 p=.004 p=.436 p=.005 p=.517 p=.082 
Platelets -.3687 1.0000 .2031 .0771 .0896 .0111 -.5636 .3974 .5904 .0988 -.0774 
 p=.023 p= --- p=.221 p=.645 p=.593 p=.947 p=.000 p=.013 p=.000 p=.555 p=.644 
Urea -.1579 .2031 1.0000 .7734 .4271 .2409 -.0153 .1363 .1297 -.5100 .0544 
 p=.344 p=.221 p= --- p=.000 p=.007 p=.145 p=.927 p=.414 p=.438 p=.001 p=.746 
Creat -.0957 .0771 .7734 1.0000 .3146 .0264 .0796 -.0022 .0245 -.6304 .1319 
 p=.568 p=.645 p=.000 p= --- p=.054 p=.875 p=.635 p=.990 p=.884 p=.000 p=.430 
Bleeding 
time 
-.0692 .0896 .4271 .3146 1.0000 .1365 -.0222 .1411 .1644 -.1577 .0044 
 p=.680 p=.593 p=.007 p=.054 p= --- p=.414 p=.895 p=.398 p=.324 p=.344 p=.979 
R value .3514 .0111 .2409 .0264 .1365 1.0000 .4659 -.1164 -.3685 -.0946 -.2780 
 p=.030 p=.947 p=.145 p=.875 p=.414 p= --- p=.003 p=.486 p=.023 p=.572 p=.091 
K value .4549 -.5636 -.0153 .0796 -.0222 .4659 1.0000 -.7068 -.6900 -.0855 .0846 
 p=.004 p=.000 p=.927 p=.635 p=.895 p=.003 p= --- p=.000 p=.000 p=.610 p=.613 
a angle -.1301 .3974 .1363 -.0022 .1411 -.1164 -.7068 1.0000 .4282 .0923 -.2092 
 p=.436 p=.013 p=.414 p=.990 p=.398 p=.486 p=.000 p= --- p=.007 p=.582 p=.207 
MA -.4433 .5904 .1297 .0245 .1644 -.3685 -.6900 .4282 1.0000 .1207 -.1743 
 p=.005 p=.000 p=.438 p=.884 p=.324 p=.023 p=.000 p=.007 p= --- p=.470 p=.295 
GFR .1084 .0988 -.5100 -.6304 -.1577 -.0946 -.0855 .0923 .1207 1.0000 -.1885 
 p=.517 p=.555 p=.001 p=.000 p=.344 p=.572 p=.610 p=.582 p=.470 p= --- p=.257 
Age -.2854 -.0774 .0544 .1319 .0044 -.2780 .0846 -.2092 -.1743 -.1885 1.0000 
 p=.082 p=.644 p=.746 p=.430 p=.979 p=.091 p=.613 p=.207 p=.295 p=.257 p= --- 
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Figure 4.1: Bar Graph of correlation of MA to patient variables 
 
When analyzing the data using a regression model, with MA as dependant variable, 
only the platelet count could reliably predict MA (p = 0.0027). This is shown in table 4.3. 
No linear regression occurred for the other variables. The haemoglobin, which showed 
a statistically significant correlation, did not demonstrate any linear regression. GFR 
was used in the regression model as it is a far more accurate measure of renal function 
than urea or creatinine alone. 
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Table 4.3 Multiple Regression of Data 
Regression Summary for Dependent Variable: MA (data) R= .65765252 R²= .43250684 Adjusted R²= 
.36371979 F(4,33)=6.2876 p 
 b* Std.Err. - of b* b Std.Err. - of b t(33) p-value 
Intercept   56.20664 6.926188 8.11509 0.000000 
Hb -0.276734 0.142850 -0.66439 0.342958 -1.93724 0.061315 
Platelets 0.465107 0.143330 0.05355 0.016503 3.24501 0.002692 
Bleeding time 0.123107 0.133577 0.23029 0.249874 0.92161 0.363420 
GFR 0.124129 0.135261 0.09153 0.099740 0.91770 0.365435 
 
4.5 Conclusion 
Generally the clotting profile of chronic renal failure patients on dialysis was normal 
when measured with the TEG®. Only two of the 39 patients showed hypocoagulability 
(prolonged R time and decreased MA).  
 
The degree of renal dysfunction as measured by GFR did not predict platelet function. 
Plasma urea (often used by anaesthetists to predict platelet function) showed no 
correlation to the MA and could not predict it. 
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       CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
5.1 Discussion of statistical results 
Chronic renal failure patients are at risk for coagulopathies. Thirty-seven of the 39 
patients investigated in this study showed a normal clotting profile, with values tending 
towards hypercoagulability. It is known that dialysis reverses platelet dysfunction in 
chronic renal failure. Since all patients included in this study had been dialysed in the 
previous 48 hours this could explain the mostly normal clotting profiles. Two of the 
patients however did show hypocoagulability despite their dialysis. It is also interesting 
to note that one of the study subjects presented to theatre some months later for a 
craniotomy for a subdural haematoma after falling. She had, however, defaulted her 
dialysis for weeks prior to the fall. At the time of the study she had a normal clotting 
profile. This further supports the fact that dialysis reverses the hypocoagulability in 
chronic renal failure patients. 
In general anaesthetic practice we are often presented with chronic renal failure patients 
in theatre. In deciding whether these patients are at risk for bleeding some anaesthetists 
assign random cut-offs for serum urea and creatinine. The general thinking is that less 
severe renal failure implies a lesser risk of bleeding. In this study only end stage renal 
failure patients were investigated and these patients were all receiving haemodialysis. 
The severity of the renal dysfunction, measured by GFR did not predict platelet function. 
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The platelet count predicted platelet function and there was a statistically significant 
correlation between the haemoglobin and MA. This is explained by the fact (mentioned 
in chapter two) that one of the causes of the coagulopathy in renal failure is anemia.  
The bleeding time was abnormal in twenty of the study patients and also could not 
predict platelet function. In fact eighteen of these twenty patients had normal clotting 
profiles. This confirms that bleeding times are poor clinical tests, of little importance in 
modern medical practice. 
 
5.2 Sample size 
Sample sizes in pilot studies are always small. Since this study used a linear regression 
model at least ten subjects were needed per regressor. There were three regressors, 
namely MA, bleeding time and platelet count. A sample size of at least 30 patients was 
required. Thirty nine in total were recruited. A larger sample size would undoubtedly 
provide more statistically significant data. 
 
5.3 The Thromboelastogram as a tool to measure coagulation 
The thromboelastogram is an in vitro test. Hence it measures in vitro coagulation. Since 
platelets not only interact with each other but also with endothelium in damaged vessels 
this interaction cannot be measured using the thromboelastogram. Therefore diseases 
which affect platelet interaction with endothelium such as Von Willebrand’s disease 
cannot be detected using the thromboelastogram. An advantage of the 
34 
 
thromboelastogram lies in the fact that it measures all constituents of the clotting 
process and gives a global indication of clotting ability. It is also a fast bedside test 
which is easy to interpret. 
In renal failure the platelet dysfunction occurs due to competitive antagonism of 
fibrinogen at the GPIIbIIIa receptor by small molecules (particularly fibrinogen 
fragments) normally filtered by the kidney. Therefore the platelet dysfunction is caused 
by a dysfunction of platelet to platelet interaction and can be measured using the TEG®. 
This is the reason why the platelet dysfunction is reversed by dialysis, as the small 
molecules are filtered. 
 
5.4 Implications for daily practice 
All chronic renal failure patients are at risk of bleeding, due to a hypocoagulable state, 
mostly attributed to platelet dysfunction. Coagulation cannot be assumed to be normal if 
laboratory parameters such as serum urea and creatinine fall below certain cut-off 
values. If invasive procedures are planned for these patients, where complications could 
arise from bleeding, a thromboelastogram is a good investigation to measure clotting 
status. It is not only of value to the anaesthetist but also to the surgeon to have an 
indication of clotting status prior to surgery or procedures. 
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5.5 Implications for further research 
The study only investigated end stage chronic renal failure (stage five renal failure) 
patients presenting to theatre. Other stages of renal failure might show more predictable 
clotting patterns.  
The sample size in the study was small, as it was a pilot study. Perhaps a larger sample 
size in a further study could show a predictable coagulation pattern. 
 
5.6 Conclusion 
All end stage renal failure patients have a potential coagulopathy due to platelet 
dysfunction. This coagulopathy is reversed by dialysis but is still very unpredictable. 
Platelet function cannot be predicted by the severity of renal dysfunction. If a procedure 
in which bleeding can cause significant complications is planned, thromboelastography 
can be used to determine clotting status, prior to the procedure. A high index of 
suspicion for bleeding must be maintained for end stage chronic renal failure patients 
who have defaulted or have not received regular dialysis for whatever reason. 
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APPENDIC C: INFORMED CONSENT FORM 
 
Informed consent form 
 
 
I, _______________________________________, agree to participate in the study that Dr Wels has 
explained to me.  
 
I understand that I will be participating in a study to learn more about clotting in patients with kidney 
failure.  
 
I understand that some information about me will be collected from my file (my age, blood results for 
kidney function and blood clotting, weight and height) and that it will be treated confidentially. 
 
I understand that some blood will be taken before surgery, and some during surgery. I also understand 
that a tiny cut will be made on my forearm while I am sleeping to assess my blood clotting.  
 
I understand that my participation is entirely voluntary and that I can pull out at any time. I have Dr 
Wels’ telephone number and can contact him should I have any questions at a later stage. 
 
Signed at ______________________________ on  
____________________________ 
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APPENDIX D: COPY OF POST GRADUATE CERTIFICATE  
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APPENDIX E: DATA SHEET 
 
Name:___________________________ 
Hospital number:__________________ 
Weight:__________________________ 
Age:____________________________ 
 
FBC:____________________________ 
 
U&E:____________________________ 
 
INR:____________________________ 
 
PTT:____________________________ 
 
BT:_____________________________ 
 
TEG: 
 
